|0.43|| -0.0016 / -0.37%|
Services to the Health Industry
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drug also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
|Moshe Manor||President, Chief Executive Officer & Director|
|Tzvi Palash||Chief Operating Officer|
|Yossi Maimon||CFO, Secretary, Treasurer & Vice President|
|Yoseph Shaaltiel||Executive Vice President-Research & Development|
|Raul Chertkoff||Vice President-Medical Affairs|